249 related articles for article (PubMed ID: 23786757)
1. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
[TBL] [Abstract][Full Text] [Related]
2. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
3. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
4. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
[TBL] [Abstract][Full Text] [Related]
7. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
[TBL] [Abstract][Full Text] [Related]
8. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resectable oral squamous cell carcinoma.
Zhu D; Tan Y; Yang X; Qiao J; Yu C; Wang L; Li J; Zhang Z; Zhong L
Int J Oral Maxillofac Surg; 2014 Dec; 43(12):1418-26. PubMed ID: 25085076
[TBL] [Abstract][Full Text] [Related]
9. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma.
Zhang L; Yang X; Zhong LP; Zhou XJ; Pan HY; Wei KJ; Li J; Chen WT; Zhang ZY
J Oral Pathol Med; 2009 Apr; 38(4):362-70. PubMed ID: 18673418
[TBL] [Abstract][Full Text] [Related]
11. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
[TBL] [Abstract][Full Text] [Related]
12. Annexin A1 down-regulation in oral squamous cell carcinoma correlates to pathological differentiation grade.
Zhu DW; Yang X; Yang CZ; Ma J; Liu Y; Yan M; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
Oral Oncol; 2013 Jun; 49(6):542-50. PubMed ID: 23403091
[TBL] [Abstract][Full Text] [Related]
13. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.
Tang X; Hu YJ; Ju WT; Fu Y; Sun WW; Liu Y; Tan YR; Wang LZ; Li J; Tu YY; Zhang CP; Zhang ZY; Zhong LP
Oncol Lett; 2018 May; 15(5):8118-8124. PubMed ID: 29731919
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer.
Inhestern J; Oertel K; Stemmann V; Schmalenberg H; Dietz A; Rotter N; Veit J; Görner M; Sudhoff H; Junghanß C; Wittekindt C; Pachmann K; Guntinas-Lichius O
PLoS One; 2015; 10(7):e0132901. PubMed ID: 26186556
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
Luo SD; Chen YJ; Liu CT; Rau KM; Chen YC; Tsai HT; Chen CH; Chiu TJ
Biomed Res Int; 2015; 2015():508587. PubMed ID: 26491674
[TBL] [Abstract][Full Text] [Related]
16. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
[TBL] [Abstract][Full Text] [Related]
17. The use of topical ALA-photodynamic therapy combined with induction chemotherapy for locally advanced oral squamous cell carcinoma.
Wang X; Li N; Meng J; Wen N
Am J Otolaryngol; 2021; 42(6):103112. PubMed ID: 34214712
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Oertel K; Spiegel K; Schmalenberg H; Dietz A; Maschmeyer G; Kuhnt T; Sudhoff H; Wendt TG; Guntinas-Lichius O
BMC Cancer; 2012 Oct; 12():483. PubMed ID: 23083061
[TBL] [Abstract][Full Text] [Related]
19. Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Owonikoko TK; Sarlis NJ; Eggers C; Phelan V; Grist WJ; Chen AY; Ramalingam SS; Chen ZG; Beitler JJ; Shin DM; Khuri FR; Marcus AI
Head Neck Pathol; 2014 Mar; 8(1):66-72. PubMed ID: 23881549
[TBL] [Abstract][Full Text] [Related]
20. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
